

REMARKS

Claims 1, 5-9, 10 and 14 are pending. Claims 2-4 and 11-13 have been cancelled. Claims 1 and 10 of the present application have been amended. Support for the amended claims can be found throughout the specification. More specifically, the subject matter of claims 4 and 13 have been incorporated into claims 1 and 10, respectively.


Election/Restriction

Applicants wish to provisionally elect without traverse Group I, which are claims 1-4 and 10-14, drawn to a combination of an ATP-competitive inhibitor and two or more other antineoplastic agents. Applicants reserve the right to file divisional applications pertaining to the subject matter in Group II.

Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Manzari
Attorney for Applicants
Reg. No. 48,152

D a t e . 10 / 3 / 1